AstraZeneca (LON:AZN) Given “Hold” Rating at Liberum Capital
Liberum Capital reissued their hold rating on shares of AstraZeneca (LON:AZN) in a research note released on Wednesday, ThisIsMoney.Co.Uk reports.
Other equities research analysts have also issued research reports about the company. Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Thursday, July 25th. Deutsche Bank reissued a buy rating and set a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research report on Friday, July 26th. Bryan, Garnier & Co reissued a neutral rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Jefferies Financial Group cut their target price on AstraZeneca from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) and set a hold rating on the stock in a research report on Friday, May 24th. Finally, Barclays raised their target price on AstraZeneca from GBX 7,500 ($98.00) to GBX 7,600 ($99.31) and gave the stock an overweight rating in a research report on Friday, July 26th. Three analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of GBX 6,658.82 ($87.01).
AZN stock opened at GBX 7,351 ($96.05) on Wednesday. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The firm has a market cap of $96.44 billion and a price-to-earnings ratio of 42.94. The firm has a 50-day moving average of GBX 6,645.92. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 7,349.30 ($96.03).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: What is a Stop Order?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.